Gland Pharma Stock Price - ₹2,907.90 | Healthcare

‌
‌
‌

Company insights, generated from the most recent coverage.

Zero Form 483 observations from US FDA inspection at Visakhapatnam (Aug-Sep 2026) removes regulatory overhang, accelerating pending ANDA approvals and strengthening competitive moat in sterile injectables.
Read more
Q1 FY27 Net Profit surged 47% YoY to ₹317 Cr with EBITDA margin expanding to 28% (from 25%), driven by yield efficiencies and cost optimization programs.
Read more
Zero-observation status enhances credibility for high-margin CDMO partnerships, supporting expansion in the $53B US generic injectables market.
Read more

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Gland Pharma shows strong top-line growth and cash generation, but margin compression and a slowing product pipeline require attention.

Consolidated gross profit grew from ₹6,144 to ₹11,759 from Q1 FY26 to Q1 FY27 — strong top-line leverage

Consolidated adjusted EBITDA margin fell from 35% to 28% from Q1 FY26 to Q1 FY27 — cost pressures weighing on profitability

Consolidated gross profit margin improved from 59% to 65% from Q1 FY26 to Q1 FY27 — better pricing and product mix

Consolidated PAT margin dropped from 26% to 18% from Q1 FY26 to Q1 FY27 — bottom-line earnings under pressure

Consolidated net cash grew from ₹23,009 to ₹32,939 from Q1 FY26 to Q1 FY27 — healthy liquidity buffer

Consolidated new product launches declined from 12 to 4 from Q1 FY26 to Q1 FY27 — slower commercial rollout pace

Consolidated receivable days dropped from 161 days to 94 days from Q1 FY26 to Q1 FY27 — faster cash collection

B2B segment revenue crashed from ₹7,170 to ₹183 from Q1 FY26 to Q1 FY27 — severe contraction in this business line

Consolidated adjusted EBITDA climbed from ₹3,651 to ₹5,102 from Q1 FY26 to Q1 FY27 — sustained operational earnings

Consolidated net working capital rose from ₹22,853 to ₹25,932 from Q1 FY26 to Q1 FY27 — higher operational funding needs

‌
‌
‌

In the news

Gland Pharma: Fosun Pharma sells 5% stake at ₹2,763/share

3 Pharma Stocks in Focus: GMP Clearances & GSK's mRNA Flu Vaccine

CDMO Showdown: Gland, Akums, and Kwality—Three Paths to Growth

Gland Pharma Q1 profit jumps 47% YoY, shares hit 52-week high

Gland Pharma hits 52-week high, appoints Deepak Sapra as CEO

Gland Pharma-Neuland Lab Partner for Sterile API Manufacturing

Top 4 stocks to buy today: Honasa, Gland Pharma, Bata India

Gland Pharma surges 2.47% on USFDA approval for generic Sugammadex

Gland Pharma shares rise 1.92% for third straight session

5 Stock Picks for June 30: Piramal Finance, Meesho, Others

Market Spotlight: 14 stocks to watch on June 12 with technical targets

Gland Pharma hits 52-week high on strong Q3 results, Cenexi turnaround

Q4 FY26 Earnings: Winners, Losers, and Market Mayhem

Gland Pharma hits 52-week high on strong Q4 results, valuation concerns persist

Gland Pharma hits 52-week high, NCC drops 7% on Q4 results

Gland Pharma hits 52-week high after Q4 results, brokerage upgrades

Gland Pharma shares surge 11% on 97% profit jump, ₹20 dividend

Gland Pharma hits 52-week high as Q4 profit nearly doubles

Gland Pharma hits 52-week high with 16% surge on strong Q4 results

Gland Pharma Q4 PAT surges 97% YoY to ₹367 crore

Gland Pharma